StockNews.AI
SPRO
StockNews.AI
154 days

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

1. Spero Therapeutics will report Q4 and full-year 2024 financial results soon. 2. Conference call scheduled for March 27, 2025, at 4:30 p.m. ET. 3. Spero develops treatments for rare diseases and multi-drug resistant bacterial infections.

Earnings
-1.26%Current Return
VS
-0.01%S&P 500
$0.770903/18 08:28 AM EDTEvent Start
$0.761203/19 02:52 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Current announcement does not provide substantial news about product progress or revenue.

How important is it?

Earnings reports typically have potential influence, but lack new product news limits impact.

Why Short Term?

Upcoming results could create immediate investor interest but lack long-term significance without major announcements.

Related Companies

SPRO
March 18, 2025 08:00 ET  | Source: Spero Therapeutics, Inc. CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this link and request a return call. The Call me™ passcode is 9270590. The audio webcast can be accessed live on this link or on the “Events and Presentations” page under the “Investor Relations” tab of the Spero Corporate Website at https://sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information, visit www.sperotherapeutics.com Investor Relations Contact:Shai Biran, PhDSpero Therapeutics IR@Sperotherapeutics.com Media Inquiries: media@sperotherapeutics.com

Related News